Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.

BACKGROUND AND AIM:Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD). Till now, few papers regarding on-treatment hepatic decompensation have been reported. The study aims to analyze the general f...

Full description

Bibliographic Details
Main Authors: Yi-Chung Hsieh, Wen-Juei Jeng, Chien-Hao Huang, Wei Teng, Wei-Ting Chen, Yi-Cheng Chen, Shi-Ming Lin, Dar-In Tai, Chun-Yen Lin, I-Shyan Sheen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6107263?pdf=render

Internet

http://europepmc.org/articles/PMC6107263?pdf=render

Similar Items